-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on AnaptysBio, Lowers Price Target to $55

Benzinga·12/17/2025 17:32:50
语音播报
Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $70 to $55.